Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
Clinical trial NCT04496089 · COMPLETED
Trial details
- NCT number
- NCT04496089
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2020-10-27
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.